genetic peptides retatrutide 24 mg & 40 mg – Research-Grade Multi-Agonist Peptide Retatrutide Significantly Reduces Visceral Fat

Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice

Most side effects reported in clinical trials have been mild to moderate and may improve as the body adjusts during dose escalation

Research Use Only For Research Use Only

User is solely responsible for ensuring that the products sold by the Company are approved substances under the Toxic Substances Control Act if applicable to Users jurisdiction

Currently in Phase 3 clinical investigation, Retatrutide is one of the most actively researched peptides in metabolic and incretin biology

It underscores the importance of additional research to identify which patients will derive the greatest benefit with no additional risk